Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | What to look out for at ASH: focus on MPNs

Ruben Mesa • 15 Nov 2019
MPN Advances Day 2019
Myeloproliferative Neoplasms Fedratinib Momelotinib Pacritinib

Ruben Mesa, MD, FACP, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, discusses what myeloproliferative neoplams (MPNs) data to watch out for at the American Society of Hematology (ASH) Annual Meeting and Exposition 2019. This interview took place at the MPN Advances Day 2019 in London, UK.

More from Ruben Mesa

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
2:08
Real-world analysis of the MOST study: factors impacting progression to MF in patients with ET
Ruben Mesa • 9 Dec 2023
2:26
Assessing the impact of momelotinib on transfusion burden in MF: analysis of SIMPLIFY-1 & MOMENTUM
Ruben Mesa • 9 Dec 2023
2:20
Quantifying the anemia benefit of momelotinib in MF: analysis of data from SIMPLIFY-1 & SIMPLIFY-2
Ruben Mesa • 9 Dec 2023

Related Videos

1:40
The current therapeutic landscape for indolent and advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
2:13
Current and emerging treatment options for patients with MF who are ineligible for ruxolitinib
Claire Harrison • 29 Apr 2024
0:52
The unmet needs that remain for patients with systemic mastocytosis
Deepti Radia • 29 Apr 2024
2:12
The current challenges and unmet needs in myelofibrosis: clinical practice and trials
Claire Harrison • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals